Success Story: RFE Conquered: NAILG Secures EB1A Approval for Scientist Advancing Gut Health and Food Safety, Following Prior NIW Success

Client’s Testimonial:

“Everything went smoothly from day one. The instructions were clear, and the lawyers went above and beyond to ensure every detail was included. I have already recommended your firm to a couple of my friends, and 3 of them got a contract/filed with your firm, and they were happy about the process as well!”

On August 27^th, 2024, and September 10^th, 2025, we received I-140 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for a Postdoctoral Researcher in the Field of Poultry Science (Approval Notice).

General Field: Poultry Science

Position at the Time of Case Filing: Postdoctoral Researcher

Country of Origin: Lebanon

State of Residence at the Time of Filing: Georgia

Approval Notice Date: August 27^th, 2024 (NIW); September 10^th, 2025 (EB1A)

Processing Time: 5 months, 13 days (NIW); 2 months, 28 days (EB1A, Premium Processing Requested)

Case Summary:

A distinguished researcher specializing in gut microbiology, nutrition, and immunology, our client has played a pivotal role in advancing scientific understanding of infectious diseases in poultry and their implications for global food safety. With the support of the North America Immigration Law Group (NAILG), he secured both EB2-NIW and EB1A (Alien of Extraordinary Ability) approvals, an achievement that reflects the national and international significance of his research.

The client’s NIW petition was approved on August 27th, 2024, followed by an EB1A approval on September 10th, 2025, after a brief RFE review. Both petitions highlighted his proven track record of scientific leadership, innovation, and broad influence within the poultry science community.

Pioneering Research and Impactful Contributions

Holding a Ph.D. in Poultry Sciences, the petitioner has built a career focused on addressing some of the most pressing challenges in animal health and food security. His investigations have yielded novel insights into the mechanisms of necrotic enteritis, the benefits of synbiotic supplementation as an antibiotic alternative, and the development of safer, nanoparticle-based vaccines against Salmonella infection.

His scholarly record includes 22 peer-reviewed journal articles (6 first-authored) and 21 conference abstracts, with a total of 312 independent citations, placing several of his papers among the top 1% most-cited works in agricultural science. His findings have been published in top-tier journals. Furthermore, he has conducted at least 23 peer reviews for leading scientific journals, underscoring his recognition as a trusted authority in his field.

A leading expert summarized his contributions as follows:

“It is clear that [Client] is a respected poultry science researcher who has uncovered the pathogenic mechanisms of necrotic enteritis in chickens, shown the benefits of synbiotic treatment, and achieved an extensive publication record in high-quality venues.”

EB1A Approval and Outlook

NAILG’s comprehensive legal approach emphasized both the originality and real-world impact of the client’s research. Our team successfully demonstrated that his innovations represent original contributions of major significance and that his work has achieved sustained national and international acclaim.

With both NIW and EB1A petitions approved, this dual success highlights not only the petitioner’s remarkable career trajectory but also NAILG’s expertise in securing approvals for scientists whose research strengthens U.S. leadership in food safety, animal health, and agricultural sustainability.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.